Protalix Biotherapeutics, Inc. (PLX) Stock Price & Analysis
Protalix Biotherapeutics, Inc. (PLX) rose 0.00% to USD 2.37 as of July 25, 2026 at 07:26 UTC, according to Nexqual real-time market data.
PLX last closed at USD 2.37; the session ranged USD 2.33–2.39 on volume of 207,148 shares. Market capitalization is $190.95M, with a 52-week range of USD 1.41–3.19 (ASE). Source: Nexqual, July 25, 2026 at 07:26 UTC.
Key Statistics (as of July 25, 2026 at 07:26 UTC)
| Price | USD 2.37 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.37 |
| Open | USD 2.35 |
| Day Range | USD 2.33 – 2.39 |
| 52-Week Range | USD 1.41 – 3.19 |
| Volume | 207,148 shares |
| Market Cap | $190.95M |
| Exchange | ASE |
Technical Analysis (PLX)
Nexqual's technical model rates PLX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.35 (neutral) |
| vs SMA50 | Above (USD 2.17) |
| MACD | 0.05 (positive) |
Analyst Ratings (PLX)
Wall Street analysts rate PLX "None" based on 2 analysts, with a mean price target of USD 11 (range USD 10–12), per Nexqual as of July 25, 2026 at 07:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 11 |
| High Target | USD 12 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (PLX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $12.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.22 vs est -0.01 ▲ beat |
| 2025-12-31 | USD -0.07 vs est 0.01 ▼ miss |
| 2025-09-30 | USD 0.03 vs est 0.06 ▼ miss |
| 2025-06-30 | USD 0 vs est 0.03 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Financials & Fundamentals (PLX)
| Total Revenue | $76.38M |
|---|---|
| Revenue Growth (YoY) | +233.70% |
| Gross Margin | +45.24% |
| Operating Margin | +62.65% |
| Profit Margin | +20.07% |
| ROE | +27.27% |
| Debt / Equity | 12.62 |
| Current Ratio | 3.15 |
| Total Cash | $51.08M |
| Total Debt | $8.48M |
| Free Cash Flow | $6.78M |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Financial Health Score (PLX)
Nexqual rates Protalix Biotherapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 07:26 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 45% |
| Balance Sheet | Strong — $51M cash vs $8M debt, net cash position |
| Cash Flow | Solid — FCF $7M, 13% margin |
| Efficiency | Strong — ROE 27%, ROA 14.0% |
Ownership (PLX)
| Insider Ownership | +3.88% |
|---|---|
| Institutional Ownership | +20.59% |
| Shares Outstanding | 80.57M |
| Float | 77.45M |
| Short % of Float | +4.80% |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
Leadership (PLX)
Protalix Biotherapeutics, Inc. is led by Dror Bashan (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 07:26 UTC.
| President, CEO & Director | Dror Bashan (age 58) |
|---|---|
| Senior VP, CFO Treasurer & Secretary | Gilad Mamlok (age 57) |
| SVP & COO | Yaron Naos B.Sc. (age 61) |
| Vice President of Human Resources | Yael Fellous |
Major Backers & Investors (PLX)
Notable institutional backers of Protalix Biotherapeutics, Inc. include MAK Capital One LLC, Renaissance Technologies, Fidelity, according to Nexqual as of July 25, 2026 at 07:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAK Capital One LLC | 4.4% |
| Renaissance Technologies | 1.52% |
| Fidelity | 0.89% |
| Stratos Wealth Partners, Ltd. | 0.62% |
| Opaleye Management Inc. | 0.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.51% |
| State Street | 1.21% |
| Northern Trust | 1.1% |
| Geode Capital | 1.07% |
| Vanguard Group | 0.98% |
Source: Nexqual, July 25, 2026 at 07:26 UTC.
From Protalix Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
- The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
- It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
- The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.
Partnerships
- Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLRX | BioLineRx Ltd. | USD 2.82 | ▼ 1.05% |
| PULM | Pulmatrix, Inc. | USD 1.65 | ▼ 2.37% |
| CANF | Can-Fite Biopharma Ltd | USD 3.19 | ▼ 3.33% |
| VSTM | Verastem, Inc. | USD 6.05 | ▲ 2.72% |
| RDHL | Redhill Biopharma Ltd. | USD 0.63 | ▼ 7.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:26 UTC. This page is informational and not investment advice.